CSL Behring Gains Haemate P Distribution Rights

Iran’s Ministry of Health and Medical Education (MOHME) has granted rights to CSL Behring to distribute Haemate P for the treatment of von Willebrand disease (VWD).

VWD is a hereditary condition caused by a deficiency or abnormality of the von Willebrand factor, a protein in the blood necessary for normal clotting.

CSL Behring said it will be the first company to bring VWD treatment to Iran.